Press ReleaseView printer-friendly version << Back
Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience
Data Were Presented at the
InPen Smart Insulin Pen Data
Medtronic presented real-world clinical results that compared glycemic outcomes for 1,736 individuals before and after using the InPen smart1 insulin pen for 90 days with a glucose monitor (CGM). Data showed an increase in Time in Range of 2.3% for people whose glucose management indicator (GMI) was >8% and an increase of 5% Time in Range for people whose GMI was >9.5%. In both groups, people did not experience any increase in
Using InPen smart insulin pen also provided improved insulin dosing decision support for those in the study as demonstrated by fewer total doses per day with simultaneously improved glycemic control. The average daily insulin bolus frequency decreased (from 3.7 to 3.6/day and 3.3 to 3.2/day, respectively, for each group) and total rapid acting daily dose of insulin increased (from 26.29 to 27.19 u/day and 27.57 to 29.24 u/day, respectively, for each group). This real-world performance analysis aggregates information from individuals who uploaded their data from
"Smart insulin pens that automatically track insulin doses and calculate active insulin are emerging as important advances in diabetes management technology because they increase the amount of time spent in the preferred glucose range without increasing hypoglycemia," said Dr.
Medtronic Extended Infusion Set Data
Medtronic also presented
During the pivotal study, the same group of patients compared their experience of wearing a 2- or 3-day set to wearing the new 7-day Medtronic extended infusion set. Overall, patients preferred the longer-wear set, rating it higher on ease of insertion, comfort of wear, duration of wear, time required to change infusion set and convenience.
"For decades, insulin infusion sets needed to be changed every two to three days. So, the development of an extended infusion set that can be worn for up to seven days represents a significant improvement in the patient experience," said
- Time in Range - Clinical consensus regarding Time in Range means that a person living with diabetes should be in the recommended range of 70-180 mg/dL (3.9 – 10 mmol/L) for at least 70% of time to be well-controlled. This may increase the likelihood that short and long-term complications of this chronic disease can be avoided.
- Glucose Management Indicator (GMI) – GMI mirrors the A1C level expected based on average glucose measured using continuous glucose monitoring (CGM) values.
- InPen - The InPen is the first and only smart insulin pen that's integrated with real-time CGM via one convenient smartphone app. The smart multiple daily injection (MDI) system automatically records insulin doses, tracks active insulin, and recommends mealtime and correction doses. By combining the InPen system with the Guardian™ Connect CGM system, individuals have access to everything they need to manage their diabetes in one place. Rather than switching between apps, users will have the ability to see real-time glucose readings and alerts as well as insulin dose information in real-time, in one view — making it easier to make informed dosing decisions to manage their glucose levels.
- Medtronic Extended Infusion Set - The Medtronic Extended infusion set is the first and only infusion set that can be worn for up to 7 days. The innovative design of the Medtronic Extended infusion set, which is designed and manufactured in collaboration with Unomedical, leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability.
About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Due to inherent study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the
1 Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration.
2 Time Below Range is time spent below 70 mg/dl.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-inpen-real-world-data-and-extended-infusion-set-pivotal-trial-results-demonstrate-strong-clinical-outcomes-and-positive-user-experience-301320702.html